TY - JOUR
T1 - Ending Gender Inequality in Cardiovascular Clinical Trial Leadership
T2 - JACC Review Topic of the Week
AU - Global CardioVascular Clinical Trialists (CVCT) Forum and Women As One Scientific Expert Panel
AU - Van Spall, Harriette G.C.
AU - Lala, Anuradha
AU - Deering, Thomas F.
AU - Casadei, Barbara
AU - Zannad, Faiez
AU - Kaul, Padma
AU - Mehran, Roxana
AU - Pearson, Gail D.
AU - Shah, Monica R.
AU - Gulati, Martha
AU - Grines, Cindy
AU - Volgman, Annabelle Santos
AU - Revkin, James H.
AU - Piña, Ileana
AU - Lam, Carolyn S.P.
AU - Hochman, Judith S.
AU - Simon, Tabassome
AU - Walsh, Mary N.
AU - Bozkurt, Biykem
N1 - Funding Information:
A majority of CV trials are funded by the pharmaceutical industry and led by men ( 17 , 26 ). Among trials of HF published in high-impact journals, pharmacotherapeutic interventions are independently associated with under-representation of women as first authors; and there is a numeric association between industry funding and under-representation of women as first authors ( 17 ). After controlling for key factors, women physicians receive significantly lower compensation for similar activities compared to men, with 75% of industry payments made to male physicians ( 46 ). These suggest that industry sponsors are “gender-unequal,” reinforcing the systemic sexism that hold women back ( 4 ).
Publisher Copyright:
© 2021 American College of Cardiology Foundation
PY - 2021/6/15
Y1 - 2021/6/15
N2 - Women are under-represented as leaders of cardiovascular randomized controlled trials, representing 1 in 10 lead authors of cardiovascular trials published in high-impact journals. Although the proportion of cardiovascular specialists who are women has increased in recent years, the proportion of cardiovascular clinical trialists who are women has not. This gap, underpinned by systemic sexism, has not been adequately addressed. The benefits of diverse randomized controlled trial leadership extend to patients and professionals. In this position statement, we present strategies adopted by some organizations to end gender inequality in research leadership. We offer an actionable roadmap for early-career researchers, scientists, academic institutions, professional societies, trial sponsors, and journals to follow, with the goal of harnessing the strength of women and under-represented groups as research leaders and facilitating a just culture in the cardiovascular clinical trial enterprise.
AB - Women are under-represented as leaders of cardiovascular randomized controlled trials, representing 1 in 10 lead authors of cardiovascular trials published in high-impact journals. Although the proportion of cardiovascular specialists who are women has increased in recent years, the proportion of cardiovascular clinical trialists who are women has not. This gap, underpinned by systemic sexism, has not been adequately addressed. The benefits of diverse randomized controlled trial leadership extend to patients and professionals. In this position statement, we present strategies adopted by some organizations to end gender inequality in research leadership. We offer an actionable roadmap for early-career researchers, scientists, academic institutions, professional societies, trial sponsors, and journals to follow, with the goal of harnessing the strength of women and under-represented groups as research leaders and facilitating a just culture in the cardiovascular clinical trial enterprise.
KW - clinical trial
KW - disparities
KW - equity
KW - gender
KW - leadership
KW - principal investigator
KW - steering committee
UR - http://www.scopus.com/inward/record.url?scp=85107027154&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2021.04.038
DO - 10.1016/j.jacc.2021.04.038
M3 - Review article
C2 - 34112322
AN - SCOPUS:85107027154
SN - 0735-1097
VL - 77
SP - 2960
EP - 2972
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 23
ER -